Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin .alpha.v.beta.3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity. Utility of the compositions disclosed may treat angiogenesis-mediated disorders such as Cancer (Solid tumors and Liquid tumors), ocular disorders (Diabetic Retinopathy and Age-related Macular Degeneration), inflammatory disorders (arthritis, osteoarthritis), atherosclerosis, lesions, and dermatology (Rosacea, Psoriasis, skin cancer) and diseases mediated or dependent upon the generation of new blood cells via angiogenesis to persist and the treatment thereof or dependent on antagonizing the formation of new blood vessels to slow or eliminate angiogenic pathways.

NANOPHARMACEUTICALS, LLC

Non-cleavable polymer conjugated with .alpha.V.beta.3 integrin thyroid antagonists

Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists

A method for binding tumor emboli circulating in the blood of mammals is provided by oral or intravenous administration of a modified alginate, prepared from alginic acid by thermal degradation/hydrolysis or enzymatic degradation. The modified alginate has a molecular weight of no more than 40,000 daltons, and is water soluble.

alginic acid/cáncer

Non-cleavable polymer conjugated with .alpha.V.beta.3 integrin thyroid antagonists

Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists

Methods for treating mammals with modified alginates and pectins

La base de datos de hierbas medicinales más completa respaldada por la ciencia